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CHAPTER I 
 
 
INTRODUCTION 
 
Cardiovascular disease (CVD) is a major health problem in many developed 
countries.  CVD is the leading cause of death in both Europe and the United States.  Each 
year in Europe, more than 4.3 million people die because of CVD, accounting for almost 
half of the total deaths in the region [1].  In the United States, about one third (830,000 
deaths) of the overall mortalities in 2006 were caused by CVD – according to data from 
National Center for Health Statistics, and over 80 million adults are believed to suffer 
some form(s) of CVD [2].  The economic burden of CVD, which is estimated from 
healthcare expenditure and the lost of productivity due to disability or death, for the 
United States alone is expected to be more than $503 billion in 2010 [3]. 
Atherosclerosis is the primary cause of CVD, including myocardial infarction, or 
heart attack, and stroke.  Atherosclerosis is a progressive disease characterized by the 
buildup of lipid substances, immune cells, and fibrous elements in the inner lining of 
large arteries (Figure 1.1) [4, 5].  The buildup is called plaque, which can grow large 
enough to significantly reduce blood flow in an artery.  However, more adverse clinical 
complications can occur when the plaque ruptures and causes a blood clot to form in the 
vessel.  The blood clot, or thrombus, can block blood flow and results in the loss of blood  
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supply to vital organs.  If the thrombus occurs in arteries that lead to the arms or legs, it 
can cause gangrene – the death of soft tissue in those body parts.  If the thrombus occurs 
in an artery leading to the heart or brain, it may cause a heart attack or stroke, 
respectively. 
 
Figure 1.1 Comparison between normal artery and one with atherosclerotic plaque.  
(Picture source: http://www.tappmedical.com/atherosclerosis.htm) 
In the past, atherosclerosis was linked to cholesterol and was believed to be 
caused by an injury to the arterial wall.  Due to advances in vascular biology, 
atherosclerosis is now viewed as an inflammatory disease, as suggested by Russell Ross 
[6].  Risk factors associated with the disease include, but not limit to, high blood pressure 
(hypertension), cigarette smoking, diabetes, and high cholesterol (hypercholesterolemia) 
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[4, 7, 8].  The initiation of the atherosclerotic lesion begins with the deposition of low-
density lipoprotein (LDL), which is a carrier of insoluble lipids, such as cholesterol in the 
water-based bloodstream, within the extracellular matrix (ECM) underneath the 
endothelial layer.  (Endothelial layer or endothelium is a single layer of cells that 
represent the inner most lining of an artery as displayed in Figure 1.1.)  The deposited 
LDL, if modified by oxidation, glycation (in case of diabetes), or other mechanisms, 
stimulates neighboring endothelial cells to send out inflammatory signals to recruit 
leukocytes or white blood cells into the area.  Modified LDL itself possesses an ability to 
attract the migration of leukocytes into the injured site as well [9].  Once leukocytes are 
localized in the subendothelial matrix, they response to the signals sent from the 
stimulated endothelial cells in various ways.  For monocytes, they differentiate into 
macrophages, which can subsequently engorge surrounding modified LDL and transform 
into foam cells.  These foam cells can also produce inflammatory signals, resulting in the 
extended number of leukocytes being recruited into the area.  If the injurious agent like 
modified LDL is still present, the whole process will continue and lead to the 
development of an atherosclerotic lesion. 
One of the important events during the initiation of atherosclerosis is the 
transendothelial migration of leukocytes.  Involved in this multi-step process are cellular 
adhesion molecules (CAMs) and chemotactic cytokines (chemokines).  CAMs are 
proteins expressed on the surface of cells and are involved with intercellular binding.  
The role of CAMs in atherosclerosis is to capture of leukocytes from the bloodstream 
onto endothelium and the transmigration of leukocytes into the ECM [10, 11].  
Chemokines are small proteins that are potent activators and attractants to leukocytes.  In 
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atherosclerosis, the recruitment of leukocytes and their successive transmigration are 
assisted by this group of proteins [11, 12].  Because both CAMs and chemokines are 
critical participants in the inflammatory process associated with atherosclerosis, they are 
suggested to be potent therapeutic targets for the treatment and prevention of this disease.  
However, a better understanding of the underlying mechanisms between these two groups 
of proteins and the progression of this disease is required in order to develop highly 
specific therapeutic strategies. 
In our laboratory, an advance three-dimensional (3D) in vitro vascular tissue 
model was introduced as a tool to study cellular mechanisms involved in the early stages 
of atherosclerosis.  The major advantage of this 3D tissue model, compared to traditional 
cell culture systems used in this field of study, is the addition of collagen matrix, which 
mimics the ECM below the endothelial layer (Figure 1.2).  Unlike the traditional cell 
culture systems, in which soluble factors that are secreted from endothelial cells dissolve 
quickly into the surrounding medium, the collagen matrix of the 3D tissue model 
provides a supplementary space that allows the gradients of the soluble factors to be 
created.  The gradients formed in the collagen matrix should mimic those formed in vivo 
in the ECM, which are responsible for the control of many cellular mechanisms.  For 
example, gradients of chemokines are known to have migratory effect on leukocytes [13-
15].  Apart from the gradients of soluble factors, when focusing on the transmigration of 
monocytes, the collagen matrix of the 3D tissue model also provides an area for 
monocytes to localize and differentiate into macrophages after the transendothelial 
migration.  This latter property of the 3D tissue model makes it applicable as a testing 
device for therapeutics of atherosclerosis in the future. 
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Figure 1.2 Comparison between traditional cell culture systems and 3D in vitro human 
vascular tissue model 
The goal of our laboratory in using the 3D tissue model is to characterize CAMs 
and chemokines that are key in the transmigration of monocytes into atherosclerotic-
lesion prone areas.  This migration process is crucial in the early stage of atherosclerosis.  
The main focus of this goal is to determine whether the capturing and successive 
migration across the endothelium of monocytes are controlled by CAMs alone, or a 
gradient of monocyte chemoattractant protein-1 (MCP-1) – a secreted chemokine that 
possesses an ability to attract monocytes – also takes part in these migration steps.  As an 
initial step to fulfill this goal, the quantification of the MCP-1 concentration gradient in 
the collagen matrix of the 3D tissue model is required.  Presently, there is no available 
technique that can be used to quantify such a gradient inside the collagen matrix directly.  
The objective of this research project is to develop a mathematical model that describes 
6 
 
both the transport and kinetic behaviors of MCP-1 in the collagen matrix of the 3D tissue 
model.  Results from this mathematical model were aimed to provide an estimation of the 
concentration gradient of MCP-1 in the collagen matrix. 
Main objective: 
 In summary, this project focuses on the development of a mathematical model 
that describes the formation of MCP-1 concentration gradient in the collagen 
matrix.  To develop the mathematical model, it is important to understand the 
transport and kinetics behaviors of MCP-1 in the matrix.  For the kinetics aspect, 
it was initially hypothesized that MCP-1 is stable at standard cell culture 
conditions (37°C in humidified atmosphere of 5% CO2 and 95% air) and there is 
no binding reaction between MCP-1 and collagen in the matrix.  Experiments 
were done to test this hypothesis. 
Sub objectives: 
 Determine the stability of MCP-1 at standard cell culture conditions. 
 Examine the binding reaction between MCP-1 and collagen in the matrix. 
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CHAPTER II 
 
 
DEVELOPMENT OF A MATHEMATICAL MODEL TO DESCRIBE THE 
TRANSPORT OF MCP-1 THROUGH A THREE-DIMENSIONAL             
COLLAGEN MATRIX 
 
Atherosclerosis is an inflammatory disease [6], which is characterized by 
endothelial dysfunction, inflammation, extracellular matrix (ECM) remodeling, and 
smooth muscle cell migration [16].  The steps in atherosclerosis plaque formation begin 
with the subendothelial accumulation of lipid substances, followed by the adhesion of 
monocytes and lymphocytes to endothelial cells and their subsequent migration across 
the endothelial layer to the ECM [17, 18].  Once localized in the subendothelial space, 
monocytes differentiate into active macrophages and form foam cells by interacting with 
oxidized low-density lipoprotein (Ox-LDL) and consuming lipid substances [6, 19].  The 
foam cells continue to produce inflammatory signals, which results in more monocyte 
recruitment to the area and the development of an atherosclerosis lesion [19].  
There are many bioactive molecules associated in the initiation of atherosclerosis 
plaque.  E-selectin and P- selectin, along with endothelial adhesion molecules, 
intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 
(VCAM-1), are found to mediate the adhesion process of leukocytes onto the endothelial 
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surface [20-22].  Monocyte chemoattractant protein-1 (MCP-1) is another bioactive 
molecule that is thought to play an important role in the formation of an early 
atherosclerosis lesion.  The function of MCP-1 in atherosclerosis includes the attraction 
of monocytes to the subendothelial matrix.  Studies show that the level of MCP-1 is 
upregulated in human atherosclerosis lesions [23, 24], and the lack of MCP-1 in a mouse 
model reduces macrophage formation [25, 26].  These experimental studies suggest that 
MCP-1 may be a potent therapeutic target for this disease. 
Monocyte trafficking across the endothelial layer is believed to be mediated by an 
MCP-1 concentration gradient.  This concept is supported by many studies [14, 15], 
including the work of Randolph and Furie [13], which illustrates in vitro that the 
transendothelial migration of monocytes depends on the soluble concentration gradient of 
MCP-1 across the endothelial layer.  It was also shown in this latter study that MCP-1 is 
equally secreted from apical and basal sides of stimulated endothelial cells [13].  This 
finding combined with the fact that MCP-1 is secreted in a soluble form suggests that in 
vivo, where the blood flow in the vascular could prevent the formation of a MCP-1 
concentration gradient in the lumen side, the concentration gradient of MCP-1 may be 
formed within the ECM via the diffusion of MCP-1 secreted from the basal of the 
endothelial layer [27].  However, information characterizing the effect of the diffusive 
gradient of MCP-1 in the subendothelial matrix to monocyte transmigration is still 
lacking.  The limitation is due to the difficulty in quantitatively determining the 
concentration of MCP-1 in the matrix. 
In the present study, we introduced the application of a 3D in vitro vascular tissue 
model [28] to investigate the formation of a diffusive gradient of MCP-1.  In contrast to a 
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traditional 2D cell culture system, where MCP-1 that is secreted from a monolayer of 
endothelial cells dissolves quickly into the surrounding media, this 3D tissue model 
provides a layer of collagen matrix in which the diffusive gradient of secreted MCP-1 can 
be formed.  The main objective of this paper is to develop a mathematical model that can 
determine MCP-1 concentration gradient within the collagen matrix.  The mathematical 
model describes both diffusive and kinetic behaviors of MCP-1 in the matrix.  The 
stability of MCP-1 under standard conditions and the binding reaction between MCP-1 
and the collagen matrix were investigated to describe the behavior of MCP-1 in the 
matrix.  In order to focus just on the behavior of MCP-1 in the collagen matrix, the 
release of MCP-1 by endothelial cells is not covered in this paper.  Instead, MCP-1 was 
added to the top reservoir of the 3D tissue model as an initial source.  For future work, 
endothelial cells will be included to the tissue model and the source term of the current 
mathematical model will be updated. 
Initial assumptions: 
Figure 2.1 shows the schematic diagram of the 3D in vitro vascular tissue model 
without cells.  The tissue model was constructed by adding collagen solution into a 
membrane well.  The cross-sectional area of the insert of the membrane well used in this 
study is 33 mm
2
.  The membrane material is polystyrene with a pore size and thickness of 
3 µm and 10 µm, respectively.  The mathematical model to determine MCP-1 
concentration gradient in the collagen matrix was developed based on the equation of 
continuity.  Several assumptions were applied to simplify the equation.  First, the 
migration of MCP-1 through the collagen matrix in the 3D vascular tissue model is 
assumed to be due to diffusive mass transfer only (no convective mass transfer occurred 
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in the system).  Second, because the focus of this study is on the gradient of MCP-1 in the 
perpendicular direction from the endothelial layer, or the top surface of the collagen 
matrix, the diffusion is assumed to be only in such direction (z-direction).  Third, the 
effect of MCP-1 mass transfer across the membrane that supports the collagen matrix is 
assumed to be insignificant compared to mass transport across the collagen matrix, 
because the thickness of the membrane is significantly less than that of the collagen 
matrix and the pore size of the membrane is significantly larger than the size of the MCP-
1 molecule.  The wall effect within the membrane well and the curvature of the top 
surface of the collagen matrix are also neglected. 
 
Figure 2.1 Schematic diagram of the 3D in vitro vascular tissue model without cells.      
A collagen matrix is formed within the well of a 24-well Transwell® plate. 
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By applying these assumptions to the equation of continuity, the main equation of the 
model becomes 
 
   (   )
  
     (
    (   )
   
)    (   ) (2.1) 
where CM is the molar concentration of MCP-1, z is the distance from the top surface of 
the collagen matrix, t is time, DM|C is the diffusivity coefficient of MCP-1 in the matrix, 
which is assumed to be constant, and RM is a rate term. 
The rate term describes the rate of MCP-1 that is reacted or consumed in the 
collagen matrix, and was still unknown at this point.  We hypothesized that MCP-1 was 
stable under standard culture conditions (37°C, and humidified atmosphere of 5% CO2 
and 95% air), and it did not bind with the collagen matrix.  The hypothesis was tested 
experimentally. 
Materials and methods: 
Materials 
Recombinant human MCP-1 was purchased from R&D Systems (Minneapolis, 
MN).  Dulbecco‟s phosphate-buffered saline (D-PBS), Medium 199, and penicillin-
streptomycin-glutamine (PSG) solution were purchased from Invitrogen (Carlsbard, CA).  
Fetal bovine serum (FBS) was purchased from Hyclone (Logan, UT).  PureCol® 
collagen (97% Type 1 collagen) was purchased from Advanced BioMatrix (San Diego, 
CA).  Sodium hydroxide was purchased from VWR (West Chester, PA).  Corning 
Transwell® permeable supports and Tween® 20 were purchased from Fisher Scientific 
(Pittsburgh, PA).  Bovine serum albumin (BSA) was purchased from Sigma-Aldrich (St. 
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Louis, MO).  BD OptEIA™ Human MCP-1 enzyme-linked immunosorbent assay 
(ELISA) set was purchased from BD Biosciences (San Jose, CA). 
MCP-1 stability test 
Complete medium (Medium 199 with 10 vol% FBS and 1 vol% PSG) was used to 
prepare MCP-1 solutions at the following concentrations: 0.25, 5, 15, 25, and 50 ng/mL.  
The MCP-1 solutions were incubated at standard conditions for 24 hours.  Samples were 
taken from the solutions every six hours during the incubation and stored at -81°C, until 
ready for analysis.  The level of MCP-1 in the samples was determined by ELISA. 
Development of the 3D in vitro vascular tissue model without cells 
The main procedure to construct the 3D vascular tissue model in this study is 
similar to the one described previously [28], but a 24-well Transwell® plate is used 
instead of a 48-well plate and no endothelial cells were seeded on top of collagen matrix.  
Briefly, collagen matrix was prepared by adding 50 µL of collagen solution containing 
57.1 vol% PureCol® collagen (3 mg/mL), 7.14 vol% Medium 199, and 35.7 vol% 0.1 M 
sodium hydroxide to each insert of a Transwell® plate.  The plate was incubated at 
standard conditions for 60 minutes for the collagen to gel.  Prior to testing, complete 
medium was added to the top and the bottom reservoirs of the plate, and the plate was 
incubated at standard conditions for four hours to equilibrate the collagen gels.   
MCP-1 binding reaction test 
 Complete medium containing one of the following concentrations of MCP-1 was 
selected as a source of MCP-1 and added to the top reservoir of the complete 3D vascular 
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tissue model without cells: 0.25, 5, 15, 25, or 50 ng/mL.  The bottom reservoir was filled 
with complete medium.  The 3D vascular tissue model was incubated at standard 
conditions for 24 hours to allow MCP-1 to diffuse from the top reservoir through the 
collagen matrix to the bottom reservoir.  During the incubation, samples were taken from 
both the top and the bottom reservoirs and were stored at -81°C, until ready for analysis.  
The MCP-1 concentration of the samples was analyzed by ELISA and was used to 
determine the binding reaction between MCP-1 and the collagen matrix. 
MCP-1 ELISA 
 ELISA was performed according to the manufacturer‟s instructions, except that 
complete medium was used as diluents for standards and samples instead of Assay 
Diluent.  The absorbance was measured with an Emax precision microplate reader 
(Molecular Devices, Sunnyvale, CA) at the 450 nm wavelength subtracted by the 540 nm 
reference wavelength.  MCP-1 concentrations were determined by comparing absorbance 
readings to those from known standard concentrations developed from the same assay. 
Statistical analysis 
 MCP-1 concentrations are expressed as mean ± SD of three samples or more.  
Student‟s t test was used to determine significant differences in the MCP-1 stability test 
results, and the estimated MCP-1 concentration in collagen matrix results.  A value of p < 
0.05 was considered significant.  Absolute-average-percentage deviation (%AAD) was 
used to compare the difference between experimental results and results from the 
mathematical model. 
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Experimental results: 
MCP-1 stability test 
Initially, it was assumed that MCP-1 is stable at standard conditions.  To test this 
assumption, complete medium containing various concentrations of MCP-1 was 
incubated at standard conditions for 24 hours. Samples were collected from the complete 
medium during that time and analyzed for the concentration of MCP-1.  The results in 
Figure 2.2 show that the concentrations of MCP-1 at the later time points (12, 18, and 24 
hours) do not change significantly when compared to the concentrations at the first time 
point (6 hours) of samples in the same group.  Thus, we concluded that MCP-1 is stable 
at standard conditions for at least 24 hours. 
 
Figure 2.2 The stability of MCP-1 at standard conditions.  Values are presented as mean 
± SD.  No significant change in concentration at later time points compared to the 
concentration at the 6-hour time point of samples within the same group                       
(the same initial concentration) was observed. 
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MCP-1 binding reaction test 
Another initial assumption was that MCP-1 does not bind with the collagen 
matrix.  This assumption was tested using the 3D vascular tissue model without cells.  
Complete medium containing a set concentration of MCP-1 was added to the top 
reservoir of the 3D vascular tissue model.  The following concentrations of MCP-1 were 
tested in the tissue model: 0.25, 5, 15, 25, or 50 ng/mL.  The model was incubated at 
standard conditions to allow MCP-1 to diffuse from the top reservoir, through the 
collagen matrix, and into the bottom reservoir, which initially contained only complete 
medium.  Samples taken from the top and the bottom reservoirs at different time points 
were analyzed for the concentration of MCP-1.  The results are shown in Figure 2.3.  
MCP-1 concentrations in both the top and the bottom reservoirs of samples with initial 
top-reservoir concentration (Ci,top) of 0.25 ng/mL were lower than the detection range of 
the ELISA kit that we used.  So, there is no data from those samples displayed in the 
figure. 
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Figure 2.3 Concentration of MCP-1 in the top (A) and the bottom (B) reservoirs of the 
3D vascular tissue model without cells.  Values are presented as mean ± SD.  ǂ represents 
the value of sample that is outside of the detection range.  So, the true value is equal to or 
greater than the value shown. 
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If the volume of the collagen matrix is known, then the data in Figure 2.3 can be 
used to calculate the average concentration of MCP-1 in the collagen matrix at each time 
point.  The collagen volume was found to be 13 µL, estimated by using the cross-
sectional area of the membrane insert and the thickness of the collagen matrix, which was 
measured microscopically to be 0.37 ± 0.06 mm.  Additional assumptions that were used 
to calculate the concentration of MCP-1 in the collagen matrix include the following: (1) 
the volumes of the top and the bottom reservoirs, and the collagen matrix are constant, 
and (2) the contents in the top and the bottom reservoirs are well mixed.  Results of the 
calculation showed that the average concentration of MCP-1 in the collagen matrix is 
higher than the concentration of MCP-1 in the top reservoir for all time points (Table 
2.1). 
However, for this experimental system, the concentration of MCP-1 in the 
collagen matrix cannot be higher than the concentration in the top reservoir, if there is no 
reaction inside the collagen matrix.  The addition of MCP-1 to the top reservoir produces 
a concentration gradient, which drives the diffusion of MCP-1 through the collagen 
matrix and into the bottom reservoir.  The diffusion will continue until MCP-1 
concentration in the system is uniformed.  Therefore, it is not possible that the 
concentration of MCP-1 in the collagen matrix is higher than in the top reservoir unless 
there is a reaction that occurs inside the collagen matrix, which consumes MCP-1 or 
transforms it from a soluble to a nonsoluble form.  Hence, this conclusion suggests that 
our initial assumption about MCP-1 binding is not accurate and that MCP-1 does bind 
with some receptors in the collagen matrix. 
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Table 2.1 Average concentration of MCP-1 in the collagen matrix. 
Samples 
Ratio of MCP-1 concentration at current time point to initial 
MCP-1 concentration in top reservoir, C/Ci,top 
6 hrs 12 hrs 18 hrs 24 hrs 
Ci,top = 5 ng/mL 
    
Top reservoir 0.460 ± 0.056 0.281 ± 0.044 0.199 ± 0.013 0.165 ± 0.005 
Collagen matrix 2.36 ± 0.27** 3.34 ± 0.72** 3.77 ± 1.13** 4.06 ± 1.13** 
Ci,top = 15 ng/mL         
Top reservoir 0.443 ± 0.024 0.243 ± 0.027 0.163 ± 0.013 0.125 ± 0.010 
Collagen matrix 1.25 ± 0.17* 2.39 ± 0.19** 1.24 ± 0.42* 1.17 ± 0.10** 
Ci,top = 25 ng/mL         
Top reservoir 0.394 ± 0.050 0.229 ± 0.005 0.123 ± 0.009 0.094 ± 0.010 
Collagen matrix ≤ 2.66 ± 0.38 2.51 ± 0.09** 3.21 ± 0.06** 2.68 ± 0.21** 
Ci,top = 50 ng/mL         
Top reservoir 0.318 ± 0.023 0.179 ± 0.020 0.122 ± 0.006 0.094 ± 0.025 
Collagen matrix 3.09 ± 0.08** 3.48 ± 0.53** 3.51 ± 0.15** 3.61 ± 0.28** 
Ci,top represents the initial MCP-1 concentration in the top reservoir.  Values shown in the 
table are presented as mean ± SD, * p < 0.05 or ** p < 0.01 for change between MCP-1 
concentration in the collagen matrix and the top reservoir at each time point. 
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Model development: 
Governing equations 
 The experimental results showed that MCP-1 is stable at standard conditions for 
at least 24 hours and it binds with the collagen matrix.  We assumed that the binding 
reaction between MCP-1 and the collagen matrix follows the general ligand-receptor 
reaction kinetics.  Evidence from a study by Distler et al. [29] has shown that, if the 
binding reaction exists, it should be an irreversible reaction.  Taking these experimental 
findings into consideration, the equation that represents the binding reaction between 
MCP-1 and the collagen matrix can be displayed as 
          (2.2) 
where M is MCP-1, S is a binding site in the collagen matrix, and M·S is a MCP-1-
binding-site complex.  To derive the rate term of the mathematical model, it was assumed 
further that for the range of MCP-1 concentrations used in this study, the rate of 
consumption of MCP-1 due to the binding reaction follows the first-order kinetics.  
However, Michaelis-Menten kinetics or Langmuir isotherm should be applied to the rate 
term when higher concentration of MCP-1 is used [30]. 
         (   ) (2.3) 
In equation (2.3), Kb is the rate constant for the binding reaction.  By substituting 
equation (2.3) into equation (2.1), the model equation becomes 
 
   (   )
  
     (
    (   )
   
)      (   ) (2.4) 
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Equation (2.4) can also be referred to as the mass balance equation of MCP-1 in the 
collagen matrix.  The concentration gradient of MCP-1 in the matrix can be determined 
by solving this equation. 
 After determining that MCP-1 can bind with the collagen matrix to form MCP-1-
binding-site (M·S) complex, we would also like to determine the concentration profile of 
the M·S complex in the matrix, as it may have a haptotactic effect on monocyte 
migration.  The equation of continuity was used again to develop the equation to 
represent the concentration of the M·S complex.  However, unlike MCP-1, which can 
diffuse through the collagen matrix, the M·S complex is assumed to be fixed inside the 
matrix.  Thus, the kinetics is the only concern in this case, and the equation to determine 
the concentration of the M·S complex was derived as 
 
     (   )
  
     (   ) (2.5) 
where CM·S is the molar concentration of the M·S complex, and RM·S is the rate of reaction 
of the M·S complex.  We know from equation (2.2) that the rate of production of the M·S 
complex is equal to the negative value of the rate of consumption of MCP-1, or 
              (   ) (2.6) 
Combining equations (2.5) and (2.6) , the equation to determine the concentration of the 
M·S complex, or the mass balance equation of the M·S complex in the collagen matrix, 
becomes 
 
     (   )
  
     (   ) (2.7) 
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Boundary conditions 
 To solve equations (2.4) and (2.7), two initial conditions for CM and CM·S and two 
boundary conditions for CM are required.  All conditions were based on the assumptions 
that the top and bottom reservoirs are well mixed, and the concentrations of MCP-1 at the 
top and the bottom surface of the collagen matrix are equal to the concentrations in the 
top and the bottom reservoirs, respectively.  Initial conditions were derived from the fact 
that initially, there was no MCP-1 in the collagen matrix or the bottom reservoir, and the 
concentration of MCP-1 in the top reservoir was known. 
   (   )    (2.8) 
   (   )         (2.9) 
Because MCP-1 was added into the top reservoir, there was no binding reaction taking 
place at the beginning and the concentration of the M·S complex was equal to zero for all 
locations. 
     (   )    (2.10) 
Next, the boundary conditions of CM were derived from the mass balance 
equations of MCP-1 in the top and the bottom reservoirs when t > 0.  Since the 
concentration of MCP-1 in the top reservoir is assumed to be equal to the concentration at 
the top surface of the collagen matrix, the convective mass transfer of MCP-1 from the 
bulk of the top reservoir to the collagen surface is neglected.  Thus, the rate of change of 
MCP-1 concentration in the top reservoir depends only on the rate of MCP-1 that diffuses 
through the top surface of the collagen matrix. 
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   (   )
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) (
   (   )
  
) (2.11) 
The relationship is the same for the change of MCP-1 concentration in the bottom 
reservoir and the diffusion of MCP-1 through the bottom surface of the collagen matrix.  
A negative sign was added to the following equation, to show the direction of MCP-1 
diffusing from the collagen matrix to the bottom reservoir. 
 
   (    )
  
  (
                   
                 
) (
   (    )
  
) (2.12) 
In equations (2.11) and (2.12), A is the surface area of either the top or the bottom surface 
of the collagen matrix, V is the volume of the top or the bottom reservoir, and zf is the 
thickness of the collagen matrix.  The area of the top and the bottom surface of the 
collagen matrix is assumed to be equal to the cross-sectional area of the membrane insert 
of the Transwell® plate.  The volumes of the top and the bottom reservoirs are the values 
set for the experiments. 
Numerical solution: 
 There were two unknown constants, DM|C and Kb, in the mathematical model.  
Their values were estimated by fitting the results of the mathematical model to 
experimental data.  Data from Figure 2.3, when the initial concentration of MCP-1 in the 
top reservoir was 5, 15, or 50 ng/mL, were selected for the regression.  The mathematical 
model was solved in MS-Excel with VBA using the Crank-Nicolson numerical method.  
The values of DM|C and Kb were determined by fitting the calculated results to the 
selected experimental data, using the weighted least squares method. 
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 To validate the estimated values of DM|C and Kb, and to evaluate the mathematical 
model, the initial concentration of MCP-1 in the top reservoir of 25 ng/mL was used to 
compare the model results to the experimental results. 
Numerical results: 
Parameter estimation 
 We found that the values of DM|C and Kb that gave the best fit to the selected 
experimental data are 0.108 mm
2
/hr and 0.858 hr
-1
, respectively.  Results of the 
regression are displayed in Figure 2.4.  From the figure, the data calculated from the 
mathematical model are about the average of the experimental data with the overall 
%AAD of 18.0%.  When considering the correlation results of the MCP-1 concentration 
in the top and the bottom reservoirs separately, the %AADs for the top- and bottom-
reservoir concentrations are 21.0% and 15.1%, respectively. 
24 
 
 
Figure 2.4 Experimental and correlated concentrations of MCP-1 in the top (A) and the 
bottom (B) reservoirs when initial MCP-1 concentration in the top reservoir was 5, 15, or 
50 ng/mL.  Experimental data are displayed as circle markers, while data from the 
mathematical model are displayed as a solid line. 
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Validation of the mathematical model 
 The mathematical model, together with the estimated values of DM|C and Kb, were 
validated with the experimental data shown in Figure 2.3, when the initial concentration 
of MCP-1 in the top reservoir was 25 ng/mL.  The validation results are displayed in 
Figure 2.5.  As observed from the figure, the mathematical model demonstrated a good 
prediction of MCP-1 concentrations in both the top and the bottom reservoirs.  The 
overall %AAD between the predicted and experimental results is 10.8%, with %AADs 
equal to 13.7% for the top-reservoir calculation and 6.8% for the bottom-reservoir 
calculation.  This low value of deviation shows that the transportation of MCP-1 in the 
3D tissue model in the first 24 hours can be represented by the formulated mathematical 
model for the initial concentration of MCP-1 in the top reservoir between 5 and 50 
ng/mL.  It is important to note here that we did not know the actual MCP-1 concentration 
in the bottom reservoir at time equal to six hours.  Due to the dilution factor used for 
sample dilution during ELISA, the detected concentration of this group of samples is 
greater than the detection range of the ELISA kit.  Therefore, the experimental data at 
that time point was not used in the mathematical-model validation, and is not displayed in 
Figure 2.5. 
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Figure 2.5 Predicted and experimental concentrations in the top (A) and the bottom (B) 
reservoirs when initial MCP-1 concentration in the top reservoir was 25 ng/mL.  
Experimental data are displayed as circle markers, while data from the model are 
displayed as a solid line. 
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MCP-1 concentration gradient in the collagen matrix 
The concentration gradients of MCP-1, both soluble and static (bound), were 
calculated using the mathematical model.  Plots showing the concentration of MCP-1 as a 
function of distance from the top surface of the collagen matrix are presented in Figure 
2.6.  The concentration gradient of soluble MCP-1 appears to be linearly dependent on 
the distance at any time point, and such gradient diminishes over time.  Contrarily, the 
concentration gradient of MCP-1 that binds to the binding sites, or the static gradient of 
MCP-1, increases as time passed and overcomes the soluble gradient of MCP-1 after two 
hours (data are not shown in the figure).  This finding suggests that, apart from the 
soluble gradient of MCP-1, the static gradient of MCP-1 is another potent factor that may 
mediate monocyte transendothelial migration. 
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Figure 2.6 Concentration gradients of MCP-1 in the collagen matrix.  Figure 2.6A shows 
the ratio of the concentration of MCP-1 that is soluble in the collagen matrix (CM (z, t)) to 
the initial concentration of MCP-1 in the top reservoir (Ci,top).  Figure 2.6B shows the 
ratio of the concentration of MCP-1 that binds with the collagen matrix (CM·S (z, t)) to the 
initial concentration of MCP-1 in the top reservoir. 
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Discussion: 
 In the present study, we developed a mathematical model to determine the 
concentration gradient of MCP-1 that formed in the collagen matrix of the 3D in vitro 
vascular tissue model without cells.  Both kinetic and transport behaviors were taken into 
account for the mathematical model development.  For the kinetics, the mathematical 
model focused mainly on the stability of MCP-1 at standard conditions and the reaction 
between MCP-1 and the collagen matrix.  Our experimental results demonstrate that 
MCP-1 is stable for at least 24 hours when it is presented as a solute in complete medium.  
However, this finding applies for recombinant MCP-1 only.  When endothelial cells are 
added to the tissue model, the stability of MCP-1 will be reevaluated, because other 
substances produced by the cells may affect MCP-1 stability. 
 A binding reaction between MCP-1 and the collagen matrix is another aspect that 
we considered during the development of the mathematical model.  Experiments were 
conducted with the 3D tissue model to determine whether the binding reaction existed.  
We concluded from experimental results that MCP-1 does bind with the collagen matrix.  
Another study investigated the time-dependent release of MCP-1 from Type 1 collagen, 
which is the main component in the collagen solution used for this study.  Results from 
this study showed that no release of MCP-1 was detected in the first 72 hours [29].  This 
result agrees with the assumption that the binding reaction between MCP-1 and the 
collagen matrix can be considered as an irreversible reaction. 
 Based on the knowledge about the MCP-1 binding reaction, two equations that 
represent the mass balance of MCP-1 and the M·S complex in the collagen matrix were 
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developed.  The values of two unknown constants, DM|C and Kb, which appear in the 
mathematical model, were found to be 0.108 mm
2
/hr and 0.858 hr
-1
, respectively.  The 
value of DM|C in this study is lower than the one calculated from an empirical equation 
used in the study of Zhao et al. [31] (0.247 mm
2
/hr) or the one reported in the study of 
Fleury et al. [32] for bioactive molecules that are in the same family as MCP-1 and have 
molecular weights close to MCP-1 (0.468-0.576 mm
2
/hr).  The difference in the values 
could be due to the methods used to determine the values.  In this study, the parameter 
DM|C was determined based on experimental data, while empirical equations for the 
estimation of the diffusivity coefficient in water and correction factors were used to 
estimate DM|C in the other two studies. 
 Results of the mathematical model show that the concentration gradient of soluble 
MCP-1 decreases over time; whereas, the static gradient of MCP-1 increases.  This 
finding is reasonable and expected for a system with a single administration of MCP-1 
and with the irreversible binding reaction.  Interestingly, the concentration of static MCP-
1, or the MCP-1 that binds with the collagen matrix, is higher than that of the soluble 
MCP-1 after two hours.  This observation is opposite to the results of a previous study, 
which showed that when applied to amnion membrane, most of the MCP-1 appears in a 
soluble form [13].  This could be due to the fact that the amnion membrane is very thin, 
by an order of magnitude, when compared to the collagen matrix used in this study.  
Moreover, the Type 1 collagen content in the amnion membrane is not as high as in the 
collagen matrix.  Both differences could result in fewer possible binding sites for MCP-1 
in the amnion membrane compared to the collagen matrix used in this study. 
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 In conclusion, a mathematical model to determine the concentration gradients of 
MCP-1 in a collagen matrix of a 3D vascular tissue model without cells was developed in 
this study.  Results of our experiments and the mathematical model suggest that there 
should be a binding reaction of MCP-1 with the collagen matrix, and such a reaction can 
produce a static gradient of MCP-1 across the matrix.  We hypothesize that the static 
gradient may also play a role during the transendothelial migration of monocytes, and 
recommend that more investigations should be done to ensure the existence of the 
binding reaction.  Furthermore, we expect that the use of this mathematical model, 
together with the 3D vascular tissue model, will provide a way to study the formation of 
the gradient of MCP-1 that is secreted from endothelial cells and the effect of the gradient 
on monocyte migration involved in the early stages of atherosclerosis.
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CHAPTER III 
 
 
EFFECT OF STORAGE CONDITIONS ON THE STABILITY OF RECOMBINANT 
HUMAN MCP-1/CCL2 
 
Chemokines (chemotatic cytokines) are low molecular weight proteins (8-12 kDa) 
that play an important role in the migration of immune cells [33].  Their functions involve 
with homeostatic mechanisms, e.g., lymphocyte trafficking or immune surveillance, as 
well as inflammatory activities, such as recruiting lymphocytes to an injured area [34, 
35].  Monocyte chemoattractant protein-1 (MCP-1 or CCL2) is a chemokine that is 
secreted by various cell types and involves in the progression of many inflammatory-
related diseases including HIV, cancer, and atherosclerosis [36].  The key function of 
MCP-1 during inflammation is to mediate the recruitment, migration, and infiltration of 
monocytes to an infected site [37]. 
Since MCP-1 was first purified more than two decades ago [38-40], a number of 
studies have been done to characterize and relate it to the pathogenesis of many diseases 
[36, 37, 41].  With the advancements in technology, MCP-1 is now commercially 
available for laboratory use in the form of recombinant protein.  Recombinant MCP-1 is 
frequently used in many in vitro studies [42-45] including those that focus on the 
transendothelial migration of monocytes [15, 46].  In our previous study, we used
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recombinant human MCP-1 to examine the formation of MCP-1 concentration gradients 
across the collagen matrix of a 3D in vitro vascular tissue model (Manuscript in review).  
Briefly, recombinant MCP-1 was added to the system, samples were collected from the 
system at various time points, and the concentration of MCP-1 in the samples were 
determined by ELISA.  The gradients of MCP-1 in the collagen matrix were estimated 
based on the concentration data.  To achieve an accurate estimation of the amount of 
MCP-1 in the system, it is important to measure accurately the concentration of MCP-1 
in the samples collected from the system.  Since the collected samples are stored at -81°C 
until ready for analysis, this raises a concern about the loss of MCP-1 during storage. 
Generally, it is suggested that recombinant MCP-1 should be stored at high 
concentration (10 µg/mL or greater) to maintain the stability of the protein.  During an 
experiment, recombinant MCP-1 is diluted to physiological relevant concentrations, with 
working concentrations in the pg/mL to ng/mL range [15, 42-46].  Consequently, samples 
that are collected from such experimental systems contain recombinant MCP-1 at lower 
concentrations than the suggested value for storage.  Thus, if those samples are not 
analyzed immediately, some MCP-1 molecules in the samples may become unstable over 
time. 
In the present study, we investigated the effect of storing conditions on the loss of 
MCP-1 in samples containing recombinant human MCP-1 at the working concentrations.  
The objectives of this study include determining 1) the loss of MCP-1 at different storage 
conditions and 2) the effect of multiple freeze-thaw cycles to the stability of MCP-1 in 
the samples.  Results of this study were aimed to provide a guideline to handle samples 
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that contain recombinant human MCP-1, but can also be applied to other recombinant 
proteins used at low working concentrations. 
Materials and methods: 
Materials 
Recombinant human MCP-1 was purchased from R&D Systems (Minneapolis, 
MN).  Dulbecco‟s phosphate-buffered saline (D-PBS), Medium 199, and penicillin-
streptomycin-glutamine (PSG) solution were purchased from Invitrogen (Carlsbard, CA).  
Fetal bovine serum (FBS) was purchased from Hyclone (Logan, UT).  Tween® 20 was 
purchased from Fisher Scientific (Pittsburgh, PA).  Bovine serum albumin (BSA) was 
purchased from Sigma-Aldrich (St. Louis, MO).  BD OptEIA™ Human MCP-1 ELISA 
Set was purchased from BD Biosciences (San Jose, CA). 
Experiments 
MCP-1 solutions were prepared from recombinant human MCP-1 and complete 
medium (Medium M199 containing 1% PSG and 10% FBS) at the following 
concentrations: 0.25, 5, 15, 25, and 50 ng/mL.  The prepared solutions were stored at 
standard conditions (37°C and humidified atmosphere of 5% CO2 and 95% air), 4°C, -
20°C, or -81°C for seven days.  On the seventh day, samples were collected from the 
solutions and analyzed immediately for the concentration of MCP-1.  After collecting the 
samples, the solutions that were previously stored at freezing conditions (-20°C and -
81°C) were frozen again at the same conditions for one more day before being thawed 
and analyzed again to determine the effect of multiple freeze-thaw cycles. 
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ELISA 
MCP-1 ELISA was performed as instructed in the manufacturer‟s manual, except 
that complete medium was used as diluents for standards and samples instead of Assay 
Diluent.  The plates were assayed on an Emax precision microplate reader (Molecular 
Devices, Sunnyvale, CA) at the 450 nm wavelength subtracted by the 540 nm reference 
wavelength.  MCP-1 concentrations were determined by comparing absorbance readings 
to a standard curve developed from the same assay. 
Statistical analysis 
MCP-1 concentrations are expressed as mean ± SD of three samples.  Significant 
differences in the results were determined using student‟s t test.  A value of p < 0.05 was 
considered significant. 
Results: 
Storing conditions 
To determine the effect of storage conditions to the loss of MCP-1 in samples, 
MCP-1 solutions were prepared from recombinant human MCP-1 and complete medium, 
and stored at different conditions for seven days.  ELISA was performed at the end of the 
storage time to determine the concentration of MCP-1.  Results are represented in Figure 
3.1.  As shown in the figure, there is no significant change in the concentration of MCP-1 
among samples with the same initial concentration, except for the 50 ng/mL samples in 
which the significant loss of MCP-1 is observed in samples that were stored at freezing 
conditions.  Results also show that if the data from 50 ng/mL samples are excluded, the 
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percent recovery of MCP-1 varies between 80% and 100%.  These two findings suggest 
that for samples with low MCP-1 concentration (≤ 25 ng/mL), recombinant human MCP-
1 in the samples is stable for all of the storage conditions tested for the seven days.  
Moreover, when comparing results from samples that were stored at non-freezing 
conditions to those stored at freezing conditions, it appears that the first freeze-thaw cycle 
does not affect the MCP-1 stability in the samples, as shown by no significant change in 
the concentration of the samples.  However, the same conclusion does not apply to 50 
ng/mL samples.  Because the significant loss of MCP-1 is only found in 50 ng/mL 
samples that were stored at freezing conditions, we believe that the loss is due to the 
freeze-thaw process and is concentration dependent. 
 
Figure 3.1 The effect of storage conditions to the stability of MCP-1.  Values are 
presented as mean ± SD, * p < 0.05 and ** p < 0.01 for changes in the concentration. 
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Multiple freeze-thaw cycles 
 The test to determine the effect of multiple freeze-thaw cycles was carried out 
after the end of the seven-day storage.  MCP-1 solutions that were previously stored at -
20°C or -81°C were collected and frozen again at the same conditions for 24 hours.  The 
samples were thawed for the second time and analyzed for the concentration of MCP-1.  
The concentration was found to decrease significantly after the second thaw for most of 
the samples that were stored at -20°C and -81°C (Figure 3.2).  The average percentage 
loss of MCP-1 due to the second thaw is 48% and 49% for the samples stored at -20°C 
and -81°C, respectively.  These results demonstrate that unlike the first freeze-thaw cycle, 
which affects only samples with high concentrations, the second freeze-thaw cycles 
results in approximately a 50% loss to recombinant human MCP-1 in all samples, 
regardless of the freezing conditions. 
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Figure 3.2 The effect of freeze-thaw cycle(s) to the stability of MCP-1.  Freezing 
conditions were selected to be -20°C (A) or -81°C (B).  Values are represented as mean ± 
SD, * p < 0.05 and ** p < 0.01 for changes in MCP-1 concentration after the second 
thaw, compared to results from the first thaw. 
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Discussion: 
The use of recombinant MCP-1 in an in vitro study generally requires that the 
recombinant protein is diluted from the stock concentration in the µg/mL range to the 
working concentrations in the pg/mL to ng/mL range.  For many studies, samples 
containing MCP-1 at the working concentrations are stored and analyzed at the end of an 
experiment to determine the concentration of MCP-1.  The stability of recombinant 
MCP-1 in samples may not be an issue if the analysis can be performed immediately after 
the collection of the samples.  However, it may be unavoidable that the samples must be 
stored for a period of time before being analyzed.  In this case, MCP-1 stability needs to 
be confirmed in order to ensure that the analyzed concentration of MCP-1 represents the 
actual concentration in the samples at the time they were collected. 
 In the present study, the stability of recombinant human MCP-1 during storage 
was examined.  MCP-1 solutions were stored at different conditions for seven days to 
evaluate the effect of short term storage.  Results show that for most of the solutions, 
recombinant MCP-1 is stable for at least seven days for all conditions tested.  It can also 
be deduced from the same results that the first freeze-thaw cycle does not affect the 
concentration of MCP-1 in most of the solutions.  However, the stability of recombinant 
MCP-1 seems to decrease as the concentration of MCP-1 in the solutions increases.  
Because the significant loss of MCP-1 was only observed in the solution that was stored 
at freezing conditions and contained the high level of MCP-1 (50 ng/mL), we believe that 
the first freeze-thaw cycle is a major contributor to such a loss and that the loss is 
concentration dependent. 
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 In our previous study, we demonstrated that recombinant human MCP-1 is stable 
at standard conditions for at least 24 hours (Manuscript in review).  Samples were 
collected every six hours from MCP-1 solutions that were incubated at standard 
conditions and stored at -81°C for one to four days before being analyzed for the 
concentration of MCP-1.  As shown in Figure 3.3 there is no significant difference 
between the concentration of samples stored at 37°C for seven days (from the current 
study) and that of samples stored at standard conditions for 6-24 hours (from the previous 
study).  This finding agrees with our conclusion that recombinant human MCP-1 is stable 
for at least seven days.  Interestingly, it appears in the figure that the freeze-thaw cycle 
did not affect the stability of MCP-1 in the previous study as it did in the present study 
for the 50 ng/mL samples.  Since in the previous study, samples were stored at -81°C for 
no more than four days, we question that time may be another factor that affects the loss 
of MCP-1 during the first freeze-thaw cycle. 
 The effect of multiple freeze-thaw cycles is another aspect being investigated in 
the present study.  Experimental results show that for both freezing conditions (-20°C and 
-81°C), the second freeze-thaw cycle causes nearly a 50% loss to the concentration of 
MCP-1 in samples.  This demonstrates that repeatedly freezing and thawing samples 
should be avoided.  Since the loss to the samples is constant, the concentration of samples 
that have gone through two freeze-thaw cycles can still be estimated.  The actual 
concentration of MCP-1 in the samples is approximately two times the concentration 
measured from an analysis after the second thaw.   
 Briefly, the stability of recombinant human MCP-1 when it is stored at working 
concentrations was investigated in this study.  Experimental results show that samples 
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containing recombinant human MCP-1 can be stored at non-freezing condition for a short 
term without significant loss of MCP-1.  However, we recommend that if samples are 
stored at freezing conditions, they should be analyzed as soon as possible because 
evidence shows that the loss of MCP-1 during the first freeze-thaw cycle may be time 
dependent.  Also, in the case of storing the samples frozen, multiple freeze-thaw cycles 
can lead to a significant loss of MCP-1 in samples and should be avoided. 
 
Figure 3.3 The comparison between results from previous and current studies.  Data 
labeled as “Previous study” are the average concentration of MCP-1 solutions that were 
incubated at standard conditions for 6-24 hours, and subsequently stored at -81°C for one 
to four days.  The concentration of MCP-1 solutions after stored at either standard 
conditions or -81°C for seven days is obtained from data in Figure 3.1 and presented as 
“Current study (37°C)” or “Current study (-81°C)”.  Values are represented as mean ± 
SD, * p < 0.05 and ** p < 0.01 for difference in MCP-1 concentration. 
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CHAPTER IV 
 
 
THE FORMATION OF A STATIC CONCENTRATION GRADIENT OF MCP-1       
IN A COLLAGEN MATRIX AND ITS HAPTOTACTIC EFFECT                              
ON MONOCYTE MIGRATION 
 
Atherosclerosis is an inflammatory disease [6] in which its initiation involves the 
infiltration of leukocytes into the vascular intima [5, 7].   An injury to the endothelium of 
a blood vessel and subsequent endothelial dysfunction are believed to be the cause of 
atherosclerosis formation [6].   Factors that may induce the injury include 
hypercholesterolemia, hypertension, diabetes, and smoking [5, 6].   The process in which 
leukocytes in the bloodstream are recruited into the injured area includes the tethering 
and slow rolling of blood-borne leukocytes on activated endothelial cells, the adhesion of 
leukocytes to the endothelium, and finally, the intravascular crawling and transmigration 
of leukocytes across the endothelial layer [10].  Each of these steps is activated by 
cellular adhesion molecules and cytokines. 
 Monocyte chemoattractant protein-1 (MCP-1 or CCL2) is a chemokine in 
the CC family that is believed to play an important role in mediating monocyte 
trafficking across the endothelial layer.  MCP-1 is secreted by various cell types, 
including endothelial cells, smooth muscle cells, and monocytes (or macrophages), which 
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are commonly found in atherosclerosis plaque [47, 48].  The fact that MCP-1 is highly 
expressed in atherosclerosis lesions elicits interest concerning the involvement of MCP-1 
in the development of this disease [23, 24, 49].  MCP-1 was confirmed to be crucial 
during the early stage of atherosclerosis by results from studies in murine models 
showing that the absence of MCP-1 reduces the formation of atherosclerosis lesion [25, 
26].  Many in vitro studies demonstrate that one of the initial steps of atherosclerosis 
involving monocyte migration is directed by the soluble gradient of MCP-1 (chemotaxis) 
[13, 14, 50-52]. 
Although it is generally accepted that the direction of monocyte migration is in 
response to the soluble gradient of MCP-1, information about the formation of such a 
gradient across the endothelium is still limited.  It was reported that MCP-1 is secreted 
from endothelial cells in a soluble form [27], and when the cells are stimulated, the 
secretion is found to be non-polarized, which means MCP-1 is secreted equally from the 
apical and basal sides of the cells [13].  Based on these two findings, Webber et al. 
suggested that in vivo, MCP-1 secreted from the apical side of the endothelium is 
continuously removed by blood flow in the lumen, while MCP-1 secreted from the basal 
side is maintained in the extracellular matrix (ECM) beneath the endothelium, thus 
forming a MCP-1 soluble gradient across the endothelium [27].  Previously, we examined 
the formation of a MCP-1 concentration gradient in the ECM using a simplified 3D in 
vitro vascular tissue model (without the addition of endothelial cells) and a mathematical 
model (Manuscript in review).  Experimental results indicated that MCP-1 binds with 
collagen in the collagen matrix of the tissue model.  We proposed that in this binding 
reaction, the soluble MCP-1 reacts with a binding site on the collagen, and a static MCP-
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1-binding site complex is formed as a product.  As a result, the static MCP-1 
concentration gradient is created in the collagen matrix, along with the gradient of soluble 
MCP-1.  Evidence from another study also suggested that the binding reaction may be 
irreversible [29]. 
 In the current study, we tested the hypothesis that the static concentration gradient 
of MCP-1 presents a haptotactic effect on the migration of monocytes.  The objectives of 
this paper are to verify the existence of the binding reaction between MCP-1 and 
collagen, and to examine the migration of moncytes in response to the static 
concentration gradient of MCP-1 (haptotaxis).  The results of this study will provide a 
better understanding of the formation of MCP-1 concentration gradients in the ECM that 
are relevant to atherosclerosis. 
Materials and methods: 
Materials 
Recombinant human MCP-1 was purchased from R&D Systems (Minneapolis, 
MN).  Dulbecco‟s phosphate-buffered saline (D-PBS), Medium 199, penicillin-
streptomycin-glutamine (PSG) solution, and Dynabeads® Untouched™ Human 
Monocytes kit were purchased from Invitrogen (Carlsbard, CA).  Fetal bovine serum 
(FBS) was purchased from Hyclone (Logan, UT).  PureCol® collagen (97% Type 1 
collagen) was purchased from Advanced BioMatrix (San Diego, CA).  Sodium hydroxide 
was purchased from VWR (West Chester, PA).  Corning Transwell® permeable 
supports, 4% paraformaldehyde in PBS, and Tween® 20 were purchased from Fisher 
Scientific (Pittsburgh, PA).  Ficoll-Paque
TM
 PLUS was purchased from GE Healthcare 
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(Uppsala, Sweden).  Bovine serum albumin (BSA) was purchased from Sigma-Aldrich 
(St. Louis, MO).  BD OptEIA™ Human MCP-1 ELISA Set was purchased from BD 
Biosciences (San Jose, CA). 
Preparation of the collage matrix of the 3D in vitro vascular tissue model 
The collagen matrix of the 3D tissue model was prepared using a procedure 
similar to what described in our previous study [28].  (The schematic diagram of the 3D 
tissue model is shown in Figure 4.1A).  Briefly, collagen solution consisting of 57.1 
vol% PureCol® collagen (3 mg/mL), 7.14 vol% Medium 199, and 35.7 vol% 0.1 M 
sodium hydroxide was added to a membrane insert of a Transwell® plate.  The plate was 
incubated at standard conditions (37°C, and humidified atmosphere of 5% CO2 and 95% 
air) for one hour to allow the collagen solution to gel.  Complete medium containing 10 
vol% FBS and 1 vol% PSG in Medium 199 was added to the top and bottom reservoirs of 
the tissue model.  The plate was incubated at standard conditions for an additional 12 
hours to equilibrate the collagen matrix.  After aspirating complete medium from the 
tissue model, the collagen matrix was ready for testing. 
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Figure 4.1 The schematic diagram of (A) 3D tissue model and (B) membrane well 
Pre-treating collagen matrix with MCP-1 
MCP-1 solution (50 ng/mL of MCP-1 in complete medium) was added into the 
top reservoir of the 3D tissue model with the collagen matrix, while the bottom reservoir 
of the model was filled with complete medium alone.  MCP-1 was allowed to diffuse 
through and react with the collagen matrix by incubating the plate at standard conditions 
for 24 hours.  Immediately after the incubation, samples were collected from the top and 
bottom reservoirs of the tissue model and both reservoirs were rinsed three times using 
complete medium to remove MCP-1 that may attach to the wall of the reservoirs.  After 
that, three successive washes were performed to ensure that soluble MCP-1 in the 
collagen matrix is completely removed.  Each successive wash was done by adding 
complete medium to the top and bottom reservoirs, placing the tissue model inside the 
incubator for one hour, and removing the remaining media from the top and bottom 
reservoirs.  The removed media and the samples that were previously collected were 
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stored at -81°C until ready for an analysis.  The concentration of MCP-1 in the samples 
was measured by ELISA. 
Monocyte isolation method 
Human peripheral blood mononuclear cells (PBMCs) were isolated by density 
gradient centrifugation on Ficoll-Paque PLUS
TM
 from the blood obtained from healthy 
donors from the Oklahoma Blood Institute (OBI) (Oklahoma City, OK).  Monocytes 
were separated from the PBMCs by magnetic bead separation.  Dynabeads® 
Untouched™ Human Monocytes kit was used to negatively select monocytes from the 
PBMC population, using the standard protocol.  Briefly, PBMCs were incubated at 
appropriate dilutions with magnetic beads coated with antibodies specific of all cell types 
within the PBMC population except for the monocyte population.  The tube containing 
the labeled sample was placed into a tube holder that induces a high-gradient magnetic 
field on the tube wall.  The labeled cells adhered to the inside surface of the tube wall, 
and the unlabeled monocytes were collected within the supernatant.  The tube was rinsed 
several times to remove all the unlabeled monocytes.  Monocytes were isolated from 
fresh blood samples and used directly in all experiments. 
Migration assay 
The collagen matrix of the 3D tissue model was prepared and either pre-treated 
with 50-ng/mL MCP-1 solutions as described in the section above, or used directly 
without pre-treating.  Complete medium containing monocytes at the density of 750,000 
cells/mL (2.27 x 10
5
 cells/cm
2
) was added to the top reservoir of the 3D tissue model, and 
complete medium alone was added to the bottom reservoir.  The tissue model was 
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incubated at standard conditions for two hours to allow monocytes to migrate into the 
collagen matrix.  To count the number of monocytes that migrated into the collagen 
matrix, media in the top and bottom reservoirs were removed, and 4% paraformaldehyde 
in PBS was added into the tissue models to immobilize the monocytes.  The number of 
monocytes in the collagen matrix was counted in five fields of view, using a light 
microscope. 
To confirm the chemotactic effect of MCP-1 on monocyte migration, the 
transmigration assay was also performed on a membrane well without the collagen matrix 
(Figure 4.1B).  Complete medium containing monocytes was added to the top reservoir 
(or the insert) of the membrane well at the same density as described previously, and a 
50-ng/mL MCP-1 solution in complete medium was added to the bottom reservoir.  For 
the control samples, complete medium without MCP-1 was added to the bottom 
reservoir.  The membrane wells were incubated for two hours at standard conditions.  
After the incubation, the top reservoir was removed and the number of monocytes that 
migrated across the membrane into the bottom reservoir was counted by using a 
hemocytometer. 
ELISA 
MCP-1 ELISA was performed as instructed in the manufacturer‟s manual, except 
that complete medium was used as diluents for standards and samples instead of Assay 
Diluent.  The plates were assayed on an Emax precision microplate reader (Molecular 
Devices, Sunnyvale, CA) at the 450 nm wavelength subtracted by the 540 nm reference 
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wavelength.  MCP-1 concentrations were determined by comparing absorbance readings 
to a standard curve developed from the same assay. 
Statistical analysis 
 Experimental results are expressed as mean ± SD of five samples.  For the results 
of the transmigration assay, student‟s t test was selected to determine a significant 
difference between the numbers of monocytes migrated into normal and pre-treated 
collagen matrix.  A value of p < 0.05 was considered significant. 
Results: 
Binding reaction between MCP-1 and collagen 
To verify the binding reaction between MCP-1 and collagen, media that were 
collected from the top and bottom reservoirs of the 3D tissue model after pre-treatment 
with 50-ng/mL MCP-1 solution and after each successive washing step were analyzed for 
the level of MCP-1.  The concentration of MCP-1 measured for each sample is presented 
in Table 4.1.  Based on these concentration data, the amounts of MCP-1 in the collagen 
matrix of the tissue model at the end of the 24-hour incubation and each washing step 
were estimated.  The calculated results show that after 24 hours of incubation, more than 
40% of the MCP-1 that was originally added to the tissue model, remained in the 
collagen matrix (Table 4.2).  The volume of the collagen matrix is calculated by 
considering the thickness of the collagen matrix to be 0.37 ± 0.06 mm (measured by 
using a light microscope at the center area of the matrix) and the cross-sectional area of a 
membrane insert to be 33 mm
2 
(given by the manufacturer).  The volume measurement is 
used to determine the average concentration of MCP-1 in the collagen matrix at this time 
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point, which is 180 ng/mL.  This concentration is nearly four times higher than the initial 
concentration of MCP-1 solution added into the tissue model and cannot be achieved if 
diffusion is the only mechanism that controls the distribution of MCP-1 in the system.  
Thus, there must be a mechanism or reaction that captures MCP-1 inside the collagen 
matrix.  Moreover, such a mechanism appears to strongly confine MCP-1 within the 
matrix as a very small portion of MCP-1 was recovered after three extensive washes.  
These findings help support our hypothesis that soluble MCP-1 does bind with collagen 
to form a static MCP-1 gradient, and that the binding reaction is irreversible. 
Table 4.1 The concentration of MCP-1 in the top and bottom reservoirs of the simplified 
3D tissue model during the pre-treatment process. 
MCP-1 concentration (ng/mL) 
After 24 hours of incubation 
 Top medium 5.23 ± 0.67 
Bottom medium 3.55 ± 0.06 
At the end of the first wash 
 Top medium 0.274 ± 0.028 
Bottom medium 0.077 ± 0.003 
At the end of the second wash 
 Top medium 0.057 ± 0.012 
Bottom medium 0.009 ± 0.001 
At the end of the third wash 
 Top medium < 0.008 
Bottom medium ≈ 0 
Values are presented as mean ± SD. 
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Table 4.2 The distribution of MCP-1 in each compartment of the simplified 3D tissue 
model during the pre-treatment process. 
Amount of MCP-1 (ng) 
Initially 
 Top medium 5 
Bottom medium 0 
Collagen matrix 0 
After 24 hours of incubation 
 Top medium 0.52 
Bottom medium 2.31 
Collagen matrix (estimated) 2.17 
At the end of the first wash 
 Top medium 0.027 
Bottom medium 0.050 
Collagen matrix (estimated) 2.10 
At the end of  the second wash 
 Top medium 0.006 
Bottom medium 0.006 
Collagen matrix (estimated) 2.08 
At the end of the third wash 
 Top medium < 0.001 
Bottom medium ≈ 0 
Collagen matrix (estimated) ≈ 2.08 
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Migration assay 
It was further hypothesized that if the binding reaction between MCP-1 and 
collagen does occur, then the concentration gradient of a MCP-1-binding site complex, 
which is a non-soluble product of the reaction, should have the same meditative effect on 
monocyte migration as the soluble gradient of MCP-1.  To test this assumption, 
monocytes were added to the top reservoir of the tissue model that was either pre-treated 
with MCP-1 or without MCP-1, and were allowed to migrate into the collagen matrix for 
two hours.  The percent of monocytes that migrated into the collagen matrix is displayed 
in Table 4.3.  Data show that the number of monocytes that migrated into the collagen 
matrix increases significantly when the collagen matrix was pre-treated with 50-ng/mL 
MCP-1 solution, compared to when it was not.  This finding further supports our 
hypothesis that the MCP-1 binding reaction and the static MCP-1 concentration gradient, 
which is caused by the reaction, do exist.  Moreover, it demonstrates that the static 
gradient of MCP-1 can induce monocyte trafficking. 
 In order to verify the chemotactic effect of MCP-1, the migration of monocytes in 
response to the soluble concentration gradient of MCP-1 was tested using a membrane 
well.  It was found that the presence of the soluble gradient of MCP-1 across the 
membrane of the testing system increased the migration of monocytes into the bottom 
reservoir by almost four times, compared to when there is no MCP-1 added into the 
system (Table 4.3).  This result confirms that MCP-1 stimulates chemotaxis of 
monocytes.  Furthermore, when compared to the increase in the migration of monocytes 
in response to the static gradient of MCP-1, which is about 1.3 times, it suggests that the 
soluble gradient of MCP-1 might have a stronger effect on the migration of monocytes 
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than the static gradient does.  However, the effect of the static gradient on monocyte 
migration also takes into account the migration into a collagen matrix; whereas, the 
soluble gradient does not. 
Table 4.3 The percent of monocytes that migrated across the membrane of a membrane 
well or into the collagen matrix of the simplified 3D tissue model.   
Monocyte migration (%) 
Across polycarbonate membrane: (for a membrane well without collagen matrix) 
When the bottom reservoir was filled with complete medium ≤ 1.8 
When the bottom reservoir was filled with 50-ng/mL MCP-1 
solution 
7.2 ± 3.0 
Into collagen matrix: (for the 3D tissue model with collagen matrix) 
When the collagen matrix is not pre-treated 23.1 ± 3.0 
When the collagen matrix is pre-treated with 50-ng/mL 
MCP-1 solution 
30.3 ± 3.7 ** 
Values are presented as mean ± SD of the percent of migrated monocytes to the initial 
numbers of monocytes added to the systems, ** p < 0.01 for change in %monocyte 
migration when the collagen matrix of the tissue model was pre-treated with MCP-1 
compared to when the matrix was not pre-treated. 
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Discussion: 
Monocyte trafficking from the bloodstream, across the endothelium, and into a 
lesion prone area is one of the key elements during the early stage of atherosclerosis.  It is 
believed that the migration of monocytes is promoted by the soluble concentration 
gradient of MCP-1.  However, the understanding about the formation of such gradient in 
subendothelial matrix is still limited.  In our recent study, we found that MCP-1 should 
be able to bind with collagen, which is a protein that is commonly found in the ECM.  
This discovery gives rise to a question that in vivo, the soluble gradient of MCP-1 may 
not be the only factor that attracts monocytes into the subendothelial matrix, but the static 
gradient of the same chemokine may play a role in the recruitment of monocytes as well. 
 In this current study, we confirmed our finding about the binding reaction 
between MCP-1 and collagen.  Results show that the combined amount of MCP-1 found 
in the top and bottom reservoirs of the 3D tissue model, after 24 hours of the addition of 
MCP-1, is only 60% of the initial amount that was added to the model.  This finding is 
similar to what we observed when we examined the formation of MCP-1 concentration 
gradient using the same tissue model (Manuscript in review).  It was also demonstrated 
that MCP-1 is stable in standard conditions for more than 24 hours, and that there is no 
significant loss of MCP-1 during the short term storage (less than four days) of samples 
before they were analyzed (Manuscripts in review).  Thus, it is reasonable to believe that 
the rest of MCP-1 remains in the tissue model and that it should localize in the collagen 
matrix of the model.  However, if all 40% of MCP-1 that resides in the collagen matrix is 
in a soluble form, then the concentration of MCP-1 in the matrix will exceed the initial 
concentration of the MCP-1 solution that was added into the tissue model.  This is not 
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possible unless there is a reaction occurring inside the collagen matrix, which consumes 
MCP-1 and changes it to other forms.  We concluded that this reaction should be the 
binding reaction between MCP-1 and collagen.  The binding reaction consumes soluble 
MCP-1 and converts it into a static product.  Based on the evidence found in a study by 
Distler et al. [29], we also proposed that the binding reaction between MCP-1 and 
collagen is irreversible.  This proposal was supported indirectly by the results of this 
study, which show that a very small amount of MCP-1 is recovered from the collagen 
matrix even after extensive washes. 
 In order to verify the existence of the binding reaction directly, we attempted to 
measure the concentration of MCP-1 in the collagen matrix.  The matrix was pre-treated 
with MCP-1 solution, to allow the binding between MCP-1 and collagen to occur, and 
washed extensively to remove any soluble MCP-1 from the matrix.  The collagen matrix 
was digested by using collagenase (Collagenase D – Roche Applied Science; 
Indianapolis, IN).  The amount of MCP-1 in the digested collagen was measured by 
ELISA.  Results reveal that no MCP-1 was detected in the digested collagen (data are not 
shown).  This finding could be due to when MCP-1 binds to collagen, the binding 
reaction may cause a conformational change to the MCP-1 molecule and thus making it 
undetectable by the antibodies used in the MCP-1 ELISA. 
 Another method, though indirect, to validate the presence of the binding reaction 
between MCP-1 and collagen is to compare the migration of monocytes into the collagen 
matrix pre-treated with MCP-1 to the collagen matrix not pre-treated with MCP-1.  We 
believed that if MCP-1 does bind with collagen, then the concentration gradient of a 
MCP-1-binding site complex, which is a product of the binding reaction, should be 
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created inside the collagen matrix.  Since MCP-1 is a chemoattractant for monocytes, and 
its soluble or chemotactic gradient has a meditative effect on monocyte migration [13, 14, 
50-52], then the gradient of static MCP-1 (or the MCP-1-binding site complex) should 
induce the migration of monocytes as well.  It was found in this study that the number of 
monocytes that migrate into the collagen matrix increases significantly when the matrix is 
pre-treated with MCP-1.  This finding not only helps confirm that the binding reaction 
does exist, but also proves that monocyte trafficking can be directed by the static or 
haptotactic gradient of MCP-1. 
 An additional transmigration assay was performed to demonstrate the effect of a 
MCP-1 soluble gradient on monocyte migration.  Results show that the soluble gradient 
of MCP-1, which was caused by adding MCP-1 solution to the bottom reservoir of a 
membrane well, increases the migration of monocytes across the membrane.  This is 
consistent with results from other studies that used similar systems to examine the effect 
of a soluble gradient of MCP-1 [50-52].  The mechanism in which the soluble gradient of 
MCP-1 stimulates monocyte migration was proven to be chemotactic, rather than 
chemokinetic [13, 50]. 
 To determine the different between the migratory effect of chemotactic and 
haptotactic gradients of MCP-1, results of the transmigration assay in the membrane well 
were compared to the one tested in the 3D tissue model.  Even though we estimated that 
the average concentration of MCP-1 in the collagen matrix of the tissue model is four 
times higher than the concentration of MCP-1 solution that was added into the membrane 
well, we found that the increased number of migrated monocytes, due to the presence of 
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the MCP-1 gradient, is higher in the membrane well (≈350%) than in the tissue model 
(≈30%).  There are two possible reasons to explain this finding.   
First, based on the results of the mathematical model that was developed in our 
previous study to determine the concentration profile of MCP-1 in the collagen matrix of 
the tissue model, most of MCP-1 in the collagen matrix is presented in the a static form 
(Manuscript in review).  (These results agree with the findings in this study, which 
demonstrate that very little soluble MCP-1 can be recovered from the collagen matrix 
that is pre-treated with MCP-1 solution.)  Moreover, several washes were also done to 
ensure that soluble MCP-1 was completely removed from the collagen matrix before the 
transmigration assay was performed.  Since the binding reaction between MCP-1 and 
collagen is irreversible, static MCP-1 does not change back to soluble MCP-1.  As a 
result, the static gradient of MCP-1 in the tissue model remains only in the collagen 
matrix.  This allows only monocytes in the top reservoir of the tissue model that are close 
to the matrix to react with the static gradient of MCP-1 in the matrix.  To the contrary, the 
soluble gradient of MCP-1 is present throughout the top reservoir of the membrane well, 
due to diffusion of the soluble MCP-1.  Thus, more monocytes can react to the gradient 
of MCP-1 in the membrane well. 
Second, for the static gradient of MCP-1 in the tissue model, the results of the 
mathematical model show that the concentration of static MCP-1 is highest at the top 
surface of the collagen matrix.  Since the migration of monocytes is in response to the 
positive gradient of MCP-1, monocytes that migrate into the collagen matrix are expected 
to stay in the area adjacent to the top surface of the matrix.  Once there become too many 
monocytes localized in that area, they may hinder the migration of other monocytes from 
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the top reservoir of the tissue model into the matrix.  This is different than what happens 
in the membrane well, where monocytes that migrate into the bottom reservoir of the well 
can move freely because there is no concentration gradient of MCP-1 in the reservoir.  
Thus, monocytes are more uniformly distributed in the bottom reservoir of the membrane 
well than in the collagen matrix of the tissue model and do not interfere with the 
migration across the membrane of other monocytes. 
Due to the aforementioned reasons, the causes of the difference between the 
chemotactic and haptotactic effects of MCP-1 that we observed in this study are believed 
to be affected by the characteristic (the first reason) and the pattern (the second reason) of 
each gradient.  We cannot determine at this point whether the chemotactic or haptotactic 
gradients of MCP-1 is more favorable to monocytes, since there are several factors – 
including the pattern of MCP-1 concentration gradient, and the amount and concentration 
of MCP-1 in the system – that may affect the migration of monocytes, but are difficult to 
control.  From these initial studies, we suspect that the soluble gradient of MCP-1 may 
have a greater chemotactic effect; however, the static gradient of MCP-1 may be 
responsible for attracting a high density of monocytes just below the endothelium, 
resulting in the site of atherosclerotic plaque formation. 
In conclusion, the formation of the static concentration gradient of MCP-1 in the 
collagen matrix of the 3D tissue model and its haptotactic effect on monocyte migration 
were examined in this study.  Experimental results show there is an irreversible binding 
reaction between MCP-1 and collagen.  Moreover, we demonstrated that static MCP-1, 
which is a product of the binding reaction, is a chemoattractant to monocytes, but may be 
less than that of the soluble MCP-1 gradient.
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CHAPTER V 
 
 
CONCLUSIONS AND RECOMMENDATIONS 
 
Conclusions: 
This research project focused on the formation of MCP-1 concentration gradients 
in the collagen matrix of the 3D in vitro vascular tissue model.  The scope of the project 
included (1) the examination of the stability of recombinant human MCP-1 under 
standard cell culture (37°C, humidified atmosphere of 95% air and 5% CO2) and storage 
(4°C, -20°C, and -81°C) conditions, (2) the investigation of the binding reaction between 
MCP-1 and collagen in the matrix, (3) the development of a mathematical model to 
predict the concentration profiles of MCP-1 in the collagen matrix, and (4) the 
exploration of the effect of a static MCP-1 concentration gradient on the migration of 
monocytes.  Conclusions are summarized as the following. 
i. Recombinant human MCP-1 maintains high stability under standard cell culture 
conditions in medium that contains at least 10% fetal bovine serum (FBS).  The 
recombinant MCP-1 can be incubated at cell culture conditions without any 
significant loss for at least seven days. 
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ii. When stored at non-freezing conditions (4°C), samples containing recombinant 
human MCP-1 and 10% FBS are stable for at least seven days.  However, if the 
samples are stored at freezing conditions (-20°C or -81°C), then the storage time, 
MCP-1 concentration of the samples, and the number of freeze-thaw cycles are 
factors that affect the stability of MCP-1. 
iii. The binding reaction between MCP-1 and collagen matrix of the 3D tissue model 
does occur and it is irreversible.  In this binding reaction, soluble MCP-1 is 
consumed and changed into static MCP-1.  As a result, the static concentration 
gradient of MCP-1 is also created in the collagen matrix. 
iv. The developed mathematical model is capable of predicting the concentration of 
both soluble and static MCP-1 in the collagen matrix of the 3D tissue model 
within the first 24 hours, when the initial concentration of MCP-1 in the top 
reservoir is between 5 ng/mL to 50 ng/mL.  The overall deviation of the 
mathematical model is estimated to be approximately 20%. 
v. The static concentration gradient of MCP-1 induces the migration of monocytes 
into the collagen matrix of the 3D tissue model.  Compared to the soluble gradient 
of MCP-1, this static gradient appears to have a weaker effect on monocytes.  
However, there are differences between the systems that were used to study the 
effects of the two gradients.  Thus, further investigation should be done to 
confirm this finding. 
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Recommendations for future studies: 
The goal of developing the mathematical model was to estimate the concentration 
gradients of MCP-1 in the collagen matrix of the 3D tissue model.  Although a layer of 
endothelial cells is neglected in this project in order to reduce the complexity of the 
mathematical model, eventually the cells need to be included as the source of MCP-1.  
The followings recommendations are for applying the current mathematical model to the 
3D tissue model with a layer of endothelial cells, as well as several suggestions to 
improve or confirm the results of the current research project. 
i. The stability of MCP-1 that is secreted from endothelial cells under cell culture 
and storing conditions needs to be evaluated, due to other substances secreted by 
the cells may affect the degradation of MCP-1. 
ii. Since MCP-1 will not be initially added to the 3D tissue model, but produced by 
endothelial cells, the rate of MCP-1 secreted by the cells needs to be determined.  
An experiment to evaluate MCP-1 secretion includes first growing endothelial 
cells in the tissue model until they are confluent and stimulating them with an 
inflammatory factor to mimic inflammatory conditions, i.e. tumor necrosis factor-
α.  Next, collecting samples from cell culture supernatant at different time points 
and measuring the concentration of MCP-1.  Finally, determining the rate of 
MCP-1 secretion by using the analytical results. 
iii. When applying the rate of MCP-1 secretion to the mathematical model, an 
additional assumption includes that MCP-1 secreted from the endothelial cells 
will be well mixed in the top reservoir of the 3D tissue model before diffuses into 
the collagen matrix.  With this assumption, the present mathematical model can 
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be used, with minimal adjustment to the Excel-VBA program that was used to 
numerically solve the model.  If results from this assumption are not satisfied, 
then a more complex form of the model must be used. 
iv. In order to further verify the existence of static MCP-1 in the collagen matrix, the 
concentration of MCP-1 should be experimentally determined.  Initial studies to 
measure the average concentration of static MCP-1 in the collagen matrix directly 
by using ELISA could not detect MCP-1.  However, this may not be the best 
method to measure the concentration of MCP-1 that binds to collagen because the 
binding may cause some changes to the molecule of MCP-1, preventing it from 
being recognized by the capture and detection antibodies used in the ELISA.  
Another way to directly verify the existence of static MCP-1 is to utilize the use 
of chromatography methods to determine the amount of MCP-1 left in the pre-
treated collagen matrix after extensive washes. 
v. One way to compare the effect of soluble and static concentration gradients of 
MCP-1 on monocyte migration is to examine the migration of monocytes into the 
3D tissue model containing both types of concentration gradients and compare to 
the migration of monocytes into the 3D tissue model with just the static 
concentration gradient.  The 3D tissue model with both the soluble and static 
concentration gradients consists of a pre-treated collagen matrix without any prior 
washing. This will give a general idea of how the addition of MCP-1 soluble 
gradient into the system with the static gradient will affect the migration of 
monocytes. 
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APPPENDICES 
 
 
APPENDIX A: DIRIVATION OF THE MATHEMATICAL MODEL 
 
Schematic diagram 
 
Figure A.1 Schematic diagram of a simplified 3D in vitro vascular tissue model 
List of assumptions 
1. There is no convective mass transfer occurring inside the collagen matrix 
2. The diffusion of MCP-1 is only in the z-direction. 
3. Since the concentration of MCP-1 is very small (in the level of ng/mL or 
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pmol/mL), the change in the MCP-1 concentration has a negligible effect on the 
total concentration of the system and, thus, the total concentration is constant. 
4. The effective diffusivity of MCP-1 in the collagen matrix is constant. 
5. The binding reaction between MCP-1 and collagen is a first-order irreversible 
reaction, and the rate of reaction depends only on the concentration of MCP-1. 
6. MCP-1-binding site (M·S) complex is a static molecule. 
7. The top and bottom reservoirs of the tissue model are well mixed. 
8. The MCP-1 concentration at the top surface of the collagen matrix is equal to the 
concentration of the top reservoir, and the MCP-1 concentration at the bottom 
surface is equal to the concentration of the bottom reservoir. 
9. The volumes of the top and bottom reservoirs are constant. 
10. The effect of mass transfer across membrane at the bottom of the collagen matrix, 
the curvature of the top surface of the collagen matrix, and wall effects are all 
neglected. 
Note:  In order to validate assumption #7, the value of the diffusivity coefficient of MCP-
1 in the collagen matrix found in this research project was compared to the diffusivity 
coefficient of MCP-1 in water.  Correlations that were used to estimate the diffusivity of 
MCP-1 in water are similar to those used in the studies of Zhao et al. [31] and Fleury et 
al. [32].  It was found that the diffusivity of MCP-1 in water is about five to six times 
higher than the diffusivity of MCP-1 in collagen matrix (values are not shown).  This 
finding suggests that MCP-1 diffuses more quickly in the top and bottom reservoirs than 
in the collagen matrix.  However, since the difference is less than one order of magnitude, 
further study should be done to confirm that this assumption is valid. 
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Mass balance equation of MCP-1 
Equation of continuity for the mass transfer of MCP-1 in the collagen matrix 
 
    
  
   ⃗ (    ⃗ 
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Apply assumption #1 to equation (A.1) 
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Expand the rate of diffusion term using Fick‟s (first) law of binary diffusion 
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Apply assumption #2 to equation (A.3) 
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     (A.4) 
Using assumptions #3 and #4, equation (A.4) can be rearranged as 
 
    
  
     
    
   
     (A.5) 
According to assumption #5, the rate of production of MCP-1 in terms of MCP-1 
concentration is 
           (A.6) 
Rate of 
change 
Rate of 
convection 
Rate of 
diffusion 
Rate of 
reaction 
1 
2 2 
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Substitute equation (A.6) into equation (A.5) 
 
    
  
     
    
   
       (A.7) 
Equation (A.7) is the mass balance equation of MCP-1 in the collagen matrix. 
Mass balance equation of MCP-1-binding site (M·S) complex 
Equation of continuity for the mass transfer of M·S complex in the collage matrix 
 
      
  
   ⃗ (      ⃗ 
 )  ( ⃗       )       (A.8) 
 
Apply the assumption #6 to equation (A.8) 
 
      
  
      (A.9) 
The rate of production of the M·S complex is equal to the rate of consumption of MCP-1, 
or 
                (A.10) 
So, the mass balance equation of the M·S complex in the collagen matrix becomes 
 
      
  
      (A.11) 
 
 
6 6 
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change 
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diffusion 
Rate of 
reaction 
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Boundary conditions 
Initially, there is no MCP-1 in the collagen matrix, and the MCP-1 solution is added to 
the top reservoir of the tissue model.  Hence, as suggested by assumptions #7 and #8, the 
initial conditions for the mass balance equations of MCP-1 and of the M·S complex are 
   (   )           (A.12) 
   (   )         (A.13) 
     (   )              (A.14) 
Two boundary conditions are required for the concentration of MCP-1.  They are derived 
by setting up the mass balance equations of MCP-1 in the top and bottom reservoirs as 
follows. 
Mass balance equation of MCP-1 in the top reservoir 
                                
Because MCP-1 is diffusing from the top reservoir to the bottom reservoir, and since 
there is no reaction that occurs inside the top reservoir, the „in‟ and „generation‟ terms are 
equal to zero.  The „accumulation‟ term is the molar change of MCP-1in the top reservoir 
over time.  The „out‟ term is the rate of MCP-1 transferred into the collagen matrix, 
which is equal to the rate of diffusion of MCP-1 at the top surface (z = 0) of the collagen 
matrix. 
 
                 
  
              (       ) (A.15) 
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Or 
 
 (                              )
  
              (       ) (A.16) 
According to assumptions #7 and #8, the concentration of MCP-1 in the top reservoir is 
equal to the concentration of MCP-1 at the top surface of the collagen matrix. 
 
 (  (   )              )
  
              (       ) (A.17) 
Apply assumption #9 to equation (A.17) and rearrange the equation 
 
 (  (   ))
  
  
            
              
(       ) (A.18) 
Expand the rate of diffusion term using Fick‟s (first) law of binary diffusion and 
assumption #3 
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(
   (   )
  
) (A.20) 
The above equation is the top boundary condition of the MCP-1 concentration. 
 
 
 
73 
 
Mass balance equation of MCP-1 in the bottom reservoir 
                                
For the bottom reservoir, the change in MCP-1 concentration is due only to the transport 
of MCP-1 from the collagen matrix.  Thus, the „out‟ and „generation‟ terms are equal to 
zero, and the „in‟ term is equal to the rate of diffusion of MCP-1 at the bottom surface (z 
= zf) of the collagen matrix. 
 
                   
  
                (        ) (A.21) 
Or 
 
 (                                   )
  
                (        ) (A.22) 
By following the same derivation as demonstrated for the top boundary condition, the 
final equation for the bottom boundary condition of MCP-1 is 
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Nondimensionalization 
In order to simplify the mathematical model and make the values of all variables bound 
between „0‟ and „1‟, nondimiensionalization is performed. 
Dimensionless variables 
Let   
  
      
 (A.24) 
   
    
      
 (A.25) 
   
 
  
 (A.26) 
   
 
  
 (A.27) 
Based on the definitions of dimensionless variables (equations (A.24-A.27)), all variables 
can be expressed in the form of dimensionless variables as follows. 
                                    
           
   (A.28) 
                                  (A.29) 
                    (A.30) 
                           
    
     (A.31) 
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A nondimensionalized mathematical model is derived by substituting all of expressions 
(A.28-A.31) into equations (A.7), (A.11), (A.12-A.14), (A20), and (A23).  The following 
are the nondimensionalized form of the mass balance equations and boundary conditions. 
Mass balance equation of MCP-1 
 
   
  
 (
      
  
 )
   
 α 
        (A.32) 
Mass balance equation of MCP-1-binding site (M·S) complex 
 
   
  
       (A.33) 
Initial conditions 
  (   )     (A.34) 
  (   )    (A.35) 
  (   )     (A.36) 
Boundary conditions 
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Numerical solution 
Since the mass balance equation of MCP-1is a linear parabolic PDE, the Crank-Nicolson 
method was selected to solve the model.  An Excel-VBA program was used to solve the 
mathematical model.  To further simplify the problem, an additional assumption, that a 
“no binding reaction occurs at the top and bottom surface of the collagen matrix”, is 
applied.  This assumption adds pseudo boundary conditions for the M·S complex to the 
mathematical model. 
  (   )     (A.39) 
  (   )     (A.40) 
It was proven that if the step size in the spatial domain is small enough, then the 
numerical solution acquired by using this assumption will be similar to when the 
assumption is not applied (data not shown). 
Notation 
   = top or bottom surface area of the collagen matrix 
   = dimensionless distance from top surface of collagen matrix 
   = total molar concentration 
        = initial molar concentration of MCP-1in top reservoir 
    = molar concentration of MCP-1 
      = molar concentration of MCP-1-binding site complex 
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      = effective diffusivity of MCP-1 in collagen matrix 
   = dimensionless concentration of MCP-1 
     = molar flux of MCP-1 
     = molar flux of MCP-1 in z-direction 
       = molar flux of MCP-1-binding site complex 
    = rate constant of the binding reaction between MCP-1 and collagen 
    = mole of MCP-1 
    = molar rate of production of MCP-1 
      = molar rate of production of MCP-1-binding site complex 
   = time 
    = final time point 
   = dimensionless concentration of MCP-1-binding site complex 
   = dimensionless time 
   = volume of top or bottom reservoir 
 ⃗    = molar average velocity 
       = Cartesian coordinates 
    = molar fraction of MCP-1 
    = thickness of collagen matrix 
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APPENDIX B: USING AN EXCEL-VBA PROGRAM TO SOLVE THE 
MATHEMATICAL MODEL NUMERICALLY 
 
An Excel-VBA program, named “Unsteady-state model” was developed and used 
to find the numerical solution of the mathematical model.  The program is divided into 
two parts.  The first part, located in a worksheet called “Main interface”, is designed to 
calculate the concentrations of soluble and static MCP-1 in the collagen matrix of the 3D 
vascular tissue model at a specified time point.  The second part, located in a worksheet 
called “Parameter regression”, is used for performing parameter regression to find the 
values of the following two unknown constants: (1) the effective diffusivity coefficient of 
MCP-1 in the collagen matrix (DM|C) and (2) the rate constant for the binding reaction 
between MCP-1 and collagen (KB).  Because the second part is generally used when one 
runs the program for the first time, the explanation on how to use the program will start 
from this part. 
Parameter regression part 
1. Open an Excel file named “Unsteady-state model.xlsm” and select “Parameter 
regression” worksheet.  The parameter regression part of the Excel-VBA program 
will appear as shown in Figure B.1. 
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Figure B.1 Parameter regression part, showing Sections 1, 2, and 3, of the Excel-VBA 
program that is designd to solve the mathematical model numerically 
 
 
Section 1 
 
Section 3 
 
 
 
 
 
 
 
 
Section 2 
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2. In Section 1 of the parameter regression part, input the physical properties, rate 
constants, and model parameters into the highlighted cells, as demonstrated in Figure 
B.2. 
2.1. The cross-sectional area of the membrane well is characteristic of the specific 
type of membrane well, and can be found in the product‟s technical datasheet. 
2.2. For this research project, the thickness of the collagen layer was approximately 
0.37 mm. 
2.3. The molecular weight of MCP-1 is 8.7 kDa. 
2.4. The diffusivity of MCP-1 in collagen (DM|C) and the rate constant for the binding 
reaction (KB) are the unknown constants being estimated, so the values are initial 
guesses. 
2.5. Because the binding reaction is irreversible, the rate constant for the releasing 
reaction (KR) is zero. 
2.6. The numbers of spatial and time nodes are set by the user.  In this research 
project, they are set to 51 and 501, respectively. 
Note: For this number of spatial node, increasing the number of time nodes beyond 
501 has a negligible effect on the regressed results.  If more precise results are 
required, the number of spatial nodes can be increased; however, this will increase 
calculation time significantly. 
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Figure B.2 Section 1 of the parameter regression part.  Users need to enter physical 
properties, rate constants, and model parameters into this section, as well as construct a 
table to calculate MCP-1 concentrations at locations and time points similar to those of 
experimental data that are used for performing parameter regression. 
3. Also in Section 1, create a table for calculating the dimensionless values of MCP-1 
concentration at the specified location and time point. 
3.1. The first column of the table indicates the location of samples, which can be 
either “Top”, or “Bottom” to represent the top reservoir or the bottom reservoir, 
respectively. 
3.2. The second column indicates the specified time point. 
3.3. The last column is the dimensionless concentration of MCP-1, calculated using 
the following function: “ConcPR(DM|C,KB,KR,Location,Time)”.  See in the 
program for an example of how to use this function. 
Note: For this research project, experimental data used for parameter regression are 
the concentration of MCP-1 in both the top and bottom reservoirs at time t = 6, 12, 
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18, and 24 hours.  Thus, dimensionless MCP-1 concentrations for the same locations 
and time points were calculated. 
4. In Section 2, create a table containing data used for parameter regression as shown in 
Figure B.3. 
4.1. Add experimental data into the “Experimental Data” side of the table as shown in 
the figure. 
4.2. The values in the column labeled “Concentration” on the “Calculated Data” side 
of the table are calculated using dimensionless MCP-1 concentration from step 3 
and the initial concentration from the “Experimental Data” side of the same table.  
See in the program for an example of the calculation. 
4.3. Use the same formulas as those in the program to calculate the values in 
“Absolute-percentage deviation” and “((ccal,i-cexp,i)/cexp,i)
2” columns. 
 
Figure B.3 Section 2 of the parameter regression part.  Experimental data that are used 
for performing parameter regression are added into this section.  Deviations between 
experimental and calculated data are also calculated in this section. 
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5. In Section 3, create a table to contain regression parameters as shown in Figure B.4.  
The equations used to calculate the absolute-average-percentage deviation (%AAD) 
and weighted-root-mean-square error (WRMS) are also displayed in the figure, as 
well as in the program. 
 
Figure B.4 Section 3 of the parameter regression part, showing overall deviation between 
experimental and calculated data.   
6. To perform parameter regression, go to tab “Data” in the Excel menu and select 
“Solver”. 
6.1. In the solver menu, set the cell that contains overall WRMS to be the target cell. 
6.2. In the next line which begins with “Equal to”, select “Value of” and enter „0‟ into 
the box. 
6.3. Set the cells containing the initial guesses for DM|C and KB to be the changing 
cells. 
6.4. In the “Subject to the Constraints” box, put in the constraints that limit the values 
of the changing cells to be equal to or more than zero. 
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6.5. Click “Solve” button and wait until the solver stops running.  This process could 
take a long time (approximately 4-6 hours). 
Note: The Solver function finds the values of DM|C and KB that give the best fit of the 
mathematical-model results to the experimental data.  (The perfect fit occurs when 
WRMS is equal to zero). 
 
Figure B.5 Microsoft Excel 2007 Solver menu 
7. Once the Solver function stops running, select the option to keep the new values of 
DM|C and KB.  The initial guess values that were previously put into the program will 
be updated to the new values. 
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Main interface part 
1. Open an Excel file named “Unsteady-state model.xlsm” and select “Main interface” 
worksheet.  (Or if the program has already been opened, select “Main interface” 
worksheet).  Main interface part of the Excel-VBA program will appear as shown in 
Figure B.6. 
2. Click “Clear” button to delete any previous results. 
3. Input the physical properties, the rate constants, and the model parameters into the 
corresponding cells. 
3.1. The values of the regressed DM|C and KB in the “Parameter regression” worksheet 
can be copied and pasted into the “Main interface” worksheet by using the “paste 
values” option. 
3.2. However, when the regressed DM|C and KB values are used, it is important to 
make sure that the numbers of spatial and time nodes in the main interface are the 
same as those used in the parameter regression.  This is because the precision of 
the MCP-1 concentration values calculated from the regressed parameters is tied 
to the number of nodes used in the calculation. 
4. When all of the required values are entered, click the “Calculate” button and wait 
until the program stops running.  The calculated concentrations of both soluble and 
static MCP-1 for each spatial node at the final time point will be displayed.  These 
values can be copied to other Excel files for further use, such as graphing. 
5. If the user needs to find MCP-1 concentrations at other time points, click the “Clear” 
button to delete the current results, then change the final time point to a new value 
and click the “Calculate” button again. 
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Figure B.6 Main interface part of the Excel-VBA program that is used to solve the 
mathematical model numerically
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